There are 2185 resources available
CN107 - The effect of Orem-based oral self-care protocol on high-dose chemotherapy-related oral mucositis and self-care agency in patients for hematologic malignancies: A randomized controlled study
Presenter: Dilek Eraslan
Session: EONS Poster Display session
Resources:
Abstract
CN108 - Comparison of symptom distress ranking between oncology nurses and pediatric patients receiving chemotherapy
Presenter: Enes Şimşek
Session: EONS Poster Display session
Resources:
Abstract
LBA65 - Efficacy of 177Lu-PNT2002 in PSMA-positive mCRPC following progression on an androgen-receptor pathway inhibitor (ARPI) (SPLASH)
Presenter: Oliver Sartor
Session: Proffered paper session: GU tumours, prostate
Resources:
Abstract
LBA25 - Randomized phase III trial of ramucirumab in combination with TAS102 (Trifluridin/Tipiracil) vs. TAS102 monotherapy in heavily pretreated metastatic colorectal cancer: The RAMTAS/IKF643 trial of the German AIO (AIO-KRK-0316)
Presenter: Stefan Kasper-Virchow
Session: Proffered paper session 2: GI tumours, lower
Resources:
Abstract
714MO - Datopotamab deruxtecan (Dato-DXd) in patients with endometrial (EC) or ovarian cancer (OC): Results from the phase II TROPION-PanTumor03 study
Presenter: Ana Oaknin
Session: Mini oral session 2: Gynaecological cancers
Resources:
Abstract
608O - Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC)
Presenter: Wungki Park
Session: Proffered paper session 2: Developmental therapeutics
Resources:
Abstract
LBA43 - 10-y survival outcomes from the phase III CheckMate 067 trial of nivolumab plus ipilimumab in advanced melanoma
Presenter: James Larkin
Session: Mini oral session: Melanoma and other skin tumours
Resources:
Abstract
502O - Pembrolizumab in combination with CAPOX and bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: Preliminary results of FFCD 1703 POCHI trial
Presenter: David Tougeron
Session: Proffered paper session 2: GI tumours, lower
Resources:
Abstract
LBA66 - UpFrontPSMA: A randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel (D) versus docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC)
Presenter: Arun Azad
Session: Proffered paper session: GU tumours, prostate
Resources:
Abstract
LBA27 - First-in-human results of STX-478, a mutant-selective PI3Ka inhibitor, in advanced solid tumor patients
Presenter: Alberto Montero
Session: Proffered paper session 2: Developmental therapeutics
Resources:
Abstract